At the 20th Congress of the European Hematology Association (EHA), Jesús F. San Miguel, MD, of the Clínica Universidad de Navarra, Navarra, Spain, discusses the results of the randomized, open-label phase 3 trial of lenalidomide plus dexamethasone with or without elotuzumab, a monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), for the treatment of patients with relapsed or refractory multiple myeloma.